Hope for Duchenne Patients: Swedish Cell Therapy Subsidiary Enters U.S. Market Following Licensing Agreement
STOCKHOLM, Sweden – 27.11.2025 – CarryGenes Therapeutics AB today announced that its subsidiary CG Bioengineering (CGB) has signed an exclusive and significant licensing agreement with U.S.-based EIRx Biologics Inc. The agreement covers the development of a new, potentially life-changing cell therapy for the serious disease Duchenne Muscular Dystrophy (DMD), based on CarryGenes' unique hSynC technology. This technology has the capacity to carry significantly larger amounts of genetic material compared to current vector methods, opening the possibility to develop even more effective treatments.
– This agreement is a milestone for CarryGenes Therapeutics and a strong validation of our unique hSynC platform's value and potential, says Lennart Dreyer, CEO of CarryGenes Therapeutics. For our shareholders and the company's stakeholders, this represents a concrete commercial validation of our technology and business model, which we aim to develop across multiple therapeutic areas. We are now seeking additional collaboration partners.
Licensing Agreement Enables Long-Term Value Creation
Under the agreement, EIRx is granted a global license to use CG Bioengineering's patented hSynC technology to develop a therapy for DMD. The agreement includes payments to CG Bioengineering tied to development milestones, creating long-term value for CarryGenes Therapeutics and its shareholders.
The Groundbreaking hSynC Technology
The hSynC technology is based on a unique, non-viral platform capable of delivering entire genes to cells – a key to treating complex genetic disorders. In the serious condition Duchenne Muscular Dystrophy, an area where CGB has advanced the hSynC technology, in-vivo studies have demonstrated the body's own production of fully functional dystrophin protein, which is key to halting disease progression. Unlike traditional viral vectors, the technology is designed to be safer and possesses a unique ability to carry both genes and their regulatory elements.
About Duchenne Muscular Dystrophy (DMD)
DMD is a serious, life-threatening muscle-wasting disease that primarily affects boys, with an incidence of approximately 1 in 3,500 newborn males. The disease is caused by a mutation in the dystrophin gene, leading to progressive muscle weakness. Symptoms begin in early childhood and often lead to wheelchair dependence by the early teenage years, with subsequent deterioration of heart and respiratory muscles, resulting in severe complications and often premature death. The current market leader in the DMD space is Sarepta, a U.S. company where a treatment costs approximately 30 million SEK.
hSynC Technology – Broad Application Potential
– Our platform technology can be applied across a very broad field, beyond human health, including in plant breeding and animal diseases. We anticipate significant interest from additional partners, concludes Lennart Dreyer.
For more information, please contact:
Lennart Dreyer, CEO
CarryGenes Therapeutics AB
Rörstrandsgatan 58, 113 40 Stockholm
Tel: +46 (0)735 00 7275
Email: lennart.dreyer@carrygenes.com
Web: www.CarryGenes.com
About CarryGenes Therapeutics AB
CarryGenes Therapeutics AB is a specialized Swedish investment company focused on biotechnology development. Through its majority ownership in its subsidiary, CarryGenes Bioengineering Inc. (USA), the company finances and drives the development of the unique hSynC platform technology – a scalable technology aimed at improving current gene therapies, such as CAR-T. Beyond the direct investment in its subsidiary, CarryGenes Therapeutics also invests in external biotech companies with adjacent activities, where the hSynC technology can contribute to accelerating and enhancing their development work